organization · Reporting owner
Pratik Shah Living Trust dated June 15, 2011
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | 10% owner | June 04, 2024 | June 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date June 04, 2024 · Filed June 08, 2024 · Amendment
Jointly reported with Shah Pratik
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Pratik Shah Living Trust dated June 15, 2011 | 7,490,404 |
Reported balance
After 2024-06-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-06-04 · Other · Disposed 2,665,800 · Balance 7,490,404 F1: The Pratik Shah Living Trust dated June 15, 2011 transferred 1,332,900 shares to The Light Irrevocable Trust #1, of which an adult son of Pratik Shah, M.D. is a beneficiary, and 1,332,900 shares to The Star Irrevocable Trust #1, of which an adult son of Dr. Shah is a beneficiary. Each transfer was made in exchange for trust assets of equal value under an asset substitution power authorized under the terms of each trust. F2: Pratik Shah, Ph.D. is the trustee of The Pratik Shah Living Trust dated June 15, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: The Pratik Shah Living Trust dated June 15, 2011 transferred 1,332,900 shares to The Light Irrevocable Trust #1, of which an adult son of Pratik Shah, M.D. is a beneficiary, and 1,332,900 shares to The Star Irrevocable Trust #1, of which an adult son of Dr. Shah is a beneficiary. Each transfer was made in exchange for trust assets of equal value under an asset substitution power authorized under the terms of each trust.
F2: Pratik Shah, Ph.D. is the trustee of The Pratik Shah Living Trust dated June 15, 2011.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2024 Filed Jun 6, 2024 20:32 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GiftCommon Stock | 1,332,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015769 · form4-06062024_080642.xml · nonDerivative · entry 3 Shah Pratik · CIK 0001580787 · Director · 10% owner Pratik Shah Living Trust dated June 15, 2011 · CIK 0001953388 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse of Pratik Shah, Ph.D. Disclosed balance after: 1,332,900 F3 · kind: This transaction involved the reporting person's gift to his spouse. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:32 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GiftCommon Stock | 1,332,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015769 · form4-06062024_080642.xml · nonDerivative · entry 2 Shah Pratik · CIK 0001580787 · Director · 10% owner Pratik Shah Living Trust dated June 15, 2011 · CIK 0001953388 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Pratik Shah Living Trust dated June 15, 2011 Disclosed balance after: 6,157,504 F3 · kind: This transaction involved the reporting person's gift to his spouse. F2 · ownership.nature: Pratik Shah, Ph.D. is the trustee of The Pratik Shah Living Trust dated June 15, 2011. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:32 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | OtherCommon Stock | 2,665,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-015769 · form4-06062024_080642.xml · nonDerivative · entry 1 Shah Pratik · CIK 0001580787 · Director · 10% owner Pratik Shah Living Trust dated June 15, 2011 · CIK 0001953388 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Pratik Shah Living Trust dated June 15, 2011 Disclosed balance after: 7,490,404 F1 · kind: The Pratik Shah Living Trust dated June 15, 2011 transferred 1,332,900 shares to The Light Irrevocable Trust #1 (the "Light Trust"), of which an adult son of Pratik Shah, M.D. is a beneficiary, and 1,332,900 shares to The Star Irrevocable Trust #1 (the "Star Trust"), of which an adult son of Dr. Shah is a beneficiary. Dr. Shah is grantor of The Light Trust and the Star Trust and therefore has the ability to terminate each trust. Each transfer was made in exchange for trust assets of equal value under an asset substitution power authorized under the terms of each trust. F1 · price: The Pratik Shah Living Trust dated June 15, 2011 transferred 1,332,900 shares to The Light Irrevocable Trust #1 (the "Light Trust"), of which an adult son of Pratik Shah, M.D. is a beneficiary, and 1,332,900 shares to The Star Irrevocable Trust #1 (the "Star Trust"), of which an adult son of Dr. Shah is a beneficiary. Dr. Shah is grantor of The Light Trust and the Star Trust and therefore has the ability to terminate each trust. Each transfer was made in exchange for trust assets of equal value under an asset substitution power authorized under the terms of each trust. F2 · ownership.nature: Pratik Shah, Ph.D. is the trustee of The Pratik Shah Living Trust dated June 15, 2011. Read SEC document |
| June 04, 2024 Filed Jun 8, 2024 01:09 UTC Amendment | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | OtherCommon Stock | 2,665,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-016094 · form4a-06082024_010607.xml · nonDerivative · entry 1 Shah Pratik · CIK 0001580787 · Director · 10% owner Pratik Shah Living Trust dated June 15, 2011 · CIK 0001953388 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Pratik Shah Living Trust dated June 15, 2011 Disclosed balance after: 7,490,404 F1 · kind: The Pratik Shah Living Trust dated June 15, 2011 transferred 1,332,900 shares to The Light Irrevocable Trust #1, of which an adult son of Pratik Shah, M.D. is a beneficiary, and 1,332,900 shares to The Star Irrevocable Trust #1, of which an adult son of Dr. Shah is a beneficiary. Each transfer was made in exchange for trust assets of equal value under an asset substitution power authorized under the terms of each trust. F1 · price: The Pratik Shah Living Trust dated June 15, 2011 transferred 1,332,900 shares to The Light Irrevocable Trust #1, of which an adult son of Pratik Shah, M.D. is a beneficiary, and 1,332,900 shares to The Star Irrevocable Trust #1, of which an adult son of Dr. Shah is a beneficiary. Each transfer was made in exchange for trust assets of equal value under an asset substitution power authorized under the terms of each trust. F2 · ownership.nature: Pratik Shah, Ph.D. is the trustee of The Pratik Shah Living Trust dated June 15, 2011. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantEmployee Stock Option (right to buy) · Derivative | 354,570 | Not disclosed Strike: $1.44 | Not disclosed |
DisclosureSEC source: 0001209191-22-056445 · doc4.xml · derivative · entry 2 Shah Pratik · CIK 0001580787 · Director · 10% owner Pratik Shah Living Trust dated June 15, 2011 · CIK 0001953388 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,570 Underlying: Common Stock · 354,570 shares Expires 2031-11-30 F4 · price: Received in exchange for a stock option to acquire 300,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement. F5 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the option vest in a series of thirty-six (36) equal monthly installments measured from the vesting commencement date. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantCommon Stock | 10,156,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-056445 · doc4.xml · nonDerivative · entry 1 Shah Pratik · CIK 0001580787 · Director · 10% owner Pratik Shah Living Trust dated June 15, 2011 · CIK 0001953388 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By The Pratik Shah Living Trust dated June 15, 2011 Disclosed balance after: 10,156,204 F1 · price: Received in exchange for 8,593,116 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. F2 · ownership.nature: These shares are held in a trust for the benefit of the Reporting Person. The Reporting Person is trustee of the trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.